Skip to main content
. 2023 May 8;58(8):893–906. doi: 10.1038/s41409-023-01997-3

Fig. 2. Relapse, non-relapse mortality, and survival outcomes according to donor type.

Fig. 2

Unadjusted cumulative incidences of relapse (a), NRM (b), and the unadjusted probabilities of OS (c), DFS (d), GRFS (e), and CRFS (f) following allogeneic HCT using MSDs, 8/8 MUDs, 7/8 MUDs, and UCB for patients with MDS over 50 years of age.